Jana Fassunke

Dr. Jana Fassunke

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MIMichaela Angelika Ihle
Michaela Angelika Ihle
JFJana Fassunke
Jana Fassunke
KKKatharina König
Katharina König
IGInga Grünewald
Inga Grünewald
MSMax Schlaak
Max Schlaak
SMSabine Merkelbach-Bruse
Sabine Merkelbach-Bruse
The approval of vemurafenib in the US 2011 and in Europe 2012 improved the therapy of not resectable or metastatic melanoma. Patients carrying a substitution of valine to glutamic acid at codon 600 (p.V600E) or a substitution of valine to leucine (p.V600K) in BRAF show complete or partial response. Therefore, the precise identification of the underlying somatic mutations is essential. Herein, we evaluate the sensitivity, specificity and feasibility of six different methods for the detection of BRAF mutations.

17 February 2023 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
CRCarolina Rosswog
Carolina Rosswog
JFJana Fassunke
Jana Fassunke
AEAngela Ernst
Angela Ernst
BSBirgid Schömig-Markiefka
Birgid Schömig-Markiefka
SMSabine Merkelbach-Bruse
Sabine Merkelbach-Bruse
MFMatthias Fischer
Matthias Fischer
Background: Genomic alterations of the anaplastic lymphoma kinase gene (ALK) occur recurrently in neuroblastoma, a pediatric malignancy of the sympathetic nervous system. However, information on their development over time has remained sparse. Methods: ALK alterations were assessed in neuroblastomas at diagnosis and/or relapse from a total of 943 patients, covering all stages of disease. Longitudinal information on diagnostic and relapsed samples from individual patients was available in 101 and 102 cases for mutation and amplification status, respectively. Results: At diagnosis, ALK point mutations occurred in 10.5% of all cases, with highest frequencies in stage 4 patients <18 months. At relapse, ALK alteration frequency increased by 70%, both in high-risk and non-high-risk cases. The increase was most likely due to de novo mutations, frequently leading to R1275Q substitutions, which are sensitive to pharmacological ALK inhibition. By contrast, the frequency of ALK amplifications did not change over the course of the disease. ALK amplifications, but not mutations, were associated with poor patient outcome. Conclusions: The considerably increased frequency of ALK mutations at relapse and their high prevalence in young stage 4 patients suggest surveying the genomic ALK status regularly in these patient cohorts, and to evaluate ALK-targeted treatment also in intermediate-risk patients.

1 September 2017 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
CAChristina Alidousty
Christina Alidousty
DBDanielle Brandes
Danielle Brandes
CHCarina Heydt
Carina Heydt
SWSvenja Wagener
Svenja Wagener
MWMaike Wittersheim
Maike Wittersheim
ASAnne M. Schultheis
Anne M. Schultheis

8 September 2017 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
JFJana Fassunke
Jana Fassunke
MIMichaela Angelika Ihle
Michaela Angelika Ihle
DLDido Lenze
Dido Lenze
ALAnnika Lehmann
Annika Lehmann
MHMichael Hummel
Michael Hummel
SMSabine Merkelbach-Bruse
Sabine Merkelbach-Bruse

7 September 2015 in International Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
JFJana Fassunke
Jana Fassunke
FHFlorian Haller
Florian Haller
SHSimone Hebele
Simone Hebele
EMEvgeny A. Moskalev
Evgeny A. Moskalev
RPRoland Penzel
Roland Penzel
VEVolker Endris
Volker Endris
In the growing field of personalised medicine, the analysis of numerous potential targets is becoming a challenge in terms of work load, tissue availability, as well as costs. The molecular analysis of non-small cell lung cancer (NSCLC) has shifted from the analysis of the epidermal growth factor receptor (EGFR) mutation status to the analysis of different gene regions, including resistance mutations or translocations. Massive parallel sequencing (MPS) allows rapid comprehensive mutation testing in routine molecular pathological diagnostics even on small formalin-fixed, paraffin‑embedded (FFPE) biopsies. In this study, we compared and evaluated currently used MPS platforms for their application in routine pathological diagnostics. We initiated a first round‑robin testing of 30 cases diagnosed with NSCLC and a known EGFR gene mutation status. In this study, three pathology institutes from Germany received FFPE tumour sections that had been individually processed. Fragment libraries were prepared by targeted multiplex PCR using institution‑specific gene panels. Sequencing was carried out using three MPS systems: MiSeq™, GS Junior and PGM Ion Torrent™. In two institutes, data analysis was performed with the platform-specific software and the Integrative Genomics Viewer. In one institute, data analysis was carried out using an in-house software system. Of 30 samples, 26 were analysed by all institutes. Concerning the EGFR mutation status, concordance was found in 26 out of 26 samples. The analysis of a few samples failed due to poor DNA quality in alternating institutes. We found 100% concordance when comparing the results of the EGFR mutation status. A total of 38 additional mutations were identified in the 26 samples. In two samples, minor variants were found which could not be confirmed by qPCR. Other characteristic variants were identified as fixation artefacts by reanalyzing the respective sample by Sanger sequencing. Overall, the results of this study demonstrated good concordance in the detection of mutations using different MPS platforms. The failure with samples can be traced back to different DNA extraction systems and DNA quality. Unknown or ambiguous variations (transitions) need verification with another method, such as qPCR or Sanger sequencing.

Verified
Journal Article
Open access
PDF file
TBThilo Bracht
Thilo Bracht
DKDaniel Kleefisch
Daniel Kleefisch
KSKarin Schork
Karin Schork
KWKathrin E. Witzke
Kathrin E. Witzke
WCWeiqiang Chen
Weiqiang Chen
BSBarbara Sitek
Barbara Sitek
Chronic obstructive pulmonary disease (COPD) is a major risk factor for the development of lung adenocarcinoma (AC). AC often develops on underlying COPD; thus, the differentiation of both entities by biomarker is challenging. Although survival of AC patients strongly depends on early diagnosis, a biomarker panel for AC detection and differentiation from COPD is still missing. Plasma samples from 176 patients with AC with or without underlying COPD, COPD patients, and hospital controls were analyzed using mass-spectrometry-based proteomics. We performed univariate statistics and additionally evaluated machine learning algorithms regarding the differentiation of AC vs. COPD and AC with COPD vs. COPD. Univariate statistics revealed significantly regulated proteins that were significantly regulated between the patient groups. Furthermore, random forest classification yielded the best performance for differentiation of AC vs. COPD (area under the curve (AUC) 0.935) and AC with COPD vs. COPD (AUC 0.916). The most influential proteins were identified by permutation feature importance and compared to those identified by univariate testing. We demonstrate the great potential of machine learning for differentiation of highly similar disease entities and present a panel of biomarker candidates that should be considered for the development of a future biomarker panel.